1887

Journal of General Virology header logo

Volume 102, Issue 4

Induction of protective immune responses against a lethal Zika virus challenge post-vaccination with a dual serotype of recombinant vesicular stomatitis virus carrying the genetically modified Zika virus E protein gene No Access

Abstract

The development of a vaccine to prevent Zika virus (ZIKV) infection has been one of the priorities in infectious disease research in recent years. There have been numerous attempts to develop an effective vaccine against ZIKV. It is imperative to choose the safest and the most effective ZIKV vaccine from all candidate vaccines to control this infection globally. We have employed a dual serotype of prime-boost recombinant vesicular stomatitis virus (VSV) vaccine strategy, to develop a ZIKV vaccine candidate, using a type 1 IFN-receptor knock-out ( ) mouse model for challenge studies. Prime vaccination with an attenuated recombinant VSV Indiana serotype (rVSV) carrying a genetically modified ZIKV envelope (E) protein gene followed by boost vaccination with attenuated recombinant VSV New Jersey serotype (rVSV) carrying the same E gene induced robust adaptive immune responses. In particular, rVSV carrying the ZIKV gene with the honeybee melittin signal peptide (msp) at the N terminus and VSV G protein transmembrane domain and cytoplasmic tail (Gtc) at the C terminus of the gene induced strong protective immune responses. This vaccine regimen induced highly potent neutralizing antibodies and T cell responses in the absence of an adjuvant and protected mice from a lethal dose of the ZIKV challenge.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): adaptive immune responses , Ifnar-/- mice , lethal Zika virus challenge , recombinant VSV vectors , vaccine and Zika virus
Funding
This study was supported by the:
  • Sumagen (Award N/A)
    • Principle Award Recipient: C.Yong Kang
  • Korea Centers for Disease Control and Prevention (KR) (Award 2018-ER5502-00)
    • Principle Award Recipient: MankiSong
  • CIHR (Award OVV-152411)
    • Principle Award Recipient: C.Yong Kang
© 2021 The Authors
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001588
2021-04-29
2024-04-16
Loading full text...

Full text loading...

References

  1. Cauchemez S, Besnard M, Bompard P, Dub T, Guillemette-Artur P et al. Association between Zika virus and microcephaly in French Polynesia, 2013-15: a retrospective study. Lancet 2016; 387:2125–2132 [View Article][PubMed]
     [Google Scholar]
  2. Schuler-Faccini L, Ribeiro EM, Feitosa IML, Horovitz DDG, Cavalcanti DP. Possible association between Zika virus infection and Microcephaly-Brazil, 2015. MMWR-CDC 2016; 65:59–62
     [Google Scholar]
  3. Brasil P, Sequeira PC, Freitas Andrea D'Avila, Zogbi HE, Calvet GA et al. Guillain-Barré syndrome associated with Zika virus infection. Lancet 2016; 387:1482 [View Article][PubMed]
     [Google Scholar]
  4. Rozé B, Najioullah F, Fergé J-L, Dorléans F, Apetse K et al. Guillain-Barré syndrome associated with Zika virus infection in Martinique in 2016: a prospective study. Clin Infect Dis 2017; 65:1462–1468 [View Article][PubMed]
     [Google Scholar]
  5. Dick GWA, Kitchen SF, Haddow AJ. Zika virus. I. isolations and serological specificity. Trans R Soc Trop Med Hyg 1952; 46:509–520 [View Article][PubMed]
     [Google Scholar]
  6. Macnamara FN. Zika virus: a report on three cases of human infection during an epidemic of jaundice in Nigeria. Trans R Soc Trop Med Hyg 1954; 48:139–145 [View Article][PubMed]
     [Google Scholar]
  7. Duffy MR, Chen T-H, Hancock WT, Powers AM, Kool JL et al. Zika virus outbreak on YAP Island, Federated states of Micronesia. N Engl J Med 2009; 360:2536–2543 [View Article][PubMed]
     [Google Scholar]
  8. Cao-Lormeau V-M, Roche C, Teissier A, Robin E, Berry A-L et al. Zika virus, French polynesia, South pacific, 2013. Emerg Infect Dis 2014; 20:1084–1086 [View Article][PubMed]
     [Google Scholar]
  9. Heukelbach J, Alencar CH, Kelvin AA, de Oliveira WK, Pamplona de Góes Cavalcanti L. Zika virus outbreak in Brazil. J Infect Dev Ctries 2016; 10:116–120 [View Article][PubMed]
     [Google Scholar]
  10. Hills SL, Fischer M, Petersen LR. Epidemiology of Zika virus infection. J Infect Dis 2017; 216:S868–S874 [View Article][PubMed]
     [Google Scholar]
  11. Abushouk AI, Negida A, Ahmed H. An updated review of Zika virus. J Clin Virol 2016; 84:53–58 [View Article][PubMed]
     [Google Scholar]
  12. Ayres CFJ. Identification of Zika virus vectors and implications for control. Lancet Infect Dis 2016; 16:278–279 [View Article][PubMed]
     [Google Scholar]
  13. Oster AM, Brooks JT, Stryker JE, Kachur RE, Mead P et al. Interim guidelines for prevention of sexual transmission of Zika virus - United States, 2016. MMWR Morb Mortal Wkly Rep 2016; 65:120–121 [View Article][PubMed]
     [Google Scholar]
  14. Knipe DM, Howley PM. Fields Virology, 5th ed. Lippincott Williams & Wilkins; 2007
     [Google Scholar]
  15. Barrett ADT. Current status of Zika vaccine development: Zika vaccines advance into clinical evaluation. NPJ Vaccines 2018; 3:24 [View Article][PubMed]
     [Google Scholar]
  16. Gaudinski MR, Houser KV, Morabito KM, Hu Z, Yamshchikov G et al. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet 2018; 391:552–562 [View Article][PubMed]
     [Google Scholar]
  17. Tebas P, Roberts CC, Muthumani K, Reuschel EL, Kudchodkar SB et al. Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine - Preliminary Report. N Engl J Med 2017 04 Oct 2017 [View Article][PubMed]
     [Google Scholar]
  18. Modjarrad K, Lin L, George SL, Stephenson KE, Eckels KH et al. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet 2018; 391:563–571 [View Article][PubMed]
     [Google Scholar]
  19. Shan C, Muruato AE, Jagger BW, Richner J, Nunes BTD et al. A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damage. Nat Commun 2017; 8:676 [View Article][PubMed]
     [Google Scholar]
  20. Shan C, Muruato AE, Nunes BTD, Luo H, Xie X et al. A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models. Nat Med 2017; 23:763–767 [View Article][PubMed]
     [Google Scholar]
  21. Kim GN, Wu K, Hong JP, Awamleh Z, Kang CY. Creation of matrix protein gene variants of two serotypes of vesicular stomatitis virus as prime-boost vaccine vectors. J Virol 2015; 89:6338–6351 [View Article][PubMed]
     [Google Scholar]
  22. Kim GN, HY A, Wu K, Banasikowska E, Harding M. Matrix protein gene variants of two serotypes of rVSV make effective viral vectors for prime-boost vaccination. J Human Virol & Retrovirol 2016; 4:00125
     [Google Scholar]
  23. An H-Y, Kim GN, Wu K, Kang CY. Genetically modified VSV(NJ) vector is capable of accommodating a large foreign gene insert and allows high level gene expression. Virus Res 2013; 171:168–177 [View Article][PubMed]
     [Google Scholar]
  24. Kim GN, Kang CY. Matrix protein of VSV New Jersey serotype containing methionine to arginine substitutions at positions 48 and 51 allows near-normal host cell gene expression. Virology 2007; 357:41–53 [View Article][PubMed]
     [Google Scholar]
  25. Emanuel J, Callison J, Dowd KA, Pierson TC, Feldmann H et al. A VSV-based Zika virus vaccine protects mice from lethal challenge. Sci Rep 2018; 8:11043 [View Article][PubMed]
     [Google Scholar]
  26. Buchholz UJ, Finke S, Conzelmann KK. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J Virol 1999; 73:251–259 [View Article][PubMed]
     [Google Scholar]
  27. Li Y, Bergeron JJ, Luo L, Ou WJ, Thomas DY et al. Effects of inefficient cleavage of the signal sequence of HIV-1 gp 120 on its association with calnexin, folding, and intracellular transport. Proc Natl Acad Sci U S A 1996; 93:9606–9611 [View Article][PubMed]
     [Google Scholar]
  28. Li Y, Luo L, Thomas DY, Kang CY. Control of expression, glycosylation, and secretion of HIV-1 gp120 by homologous and heterologous signal sequences. Virology 1994; 204:266–278 [View Article][PubMed]
     [Google Scholar]
  29. Rieger T, Merkler D, Günther S. Infection of type I interferon receptor-deficient mice with various old world arenaviruses: a model for studying virulence and host species barriers. PLoS One 2013; 8:e72290 [View Article][PubMed]
     [Google Scholar]
  30. Wei J, Ma Y, Wang L, Chi X, Yan R et al. Alpha/beta interferon receptor deficiency in mice significantly enhances susceptibility of the animals to pseudorabies virus infection. Vet Microbiol 2017; 203:234–244 [View Article][PubMed]
     [Google Scholar]
  31. Wong G, Qiu X-G. Type I interferon receptor knockout mice as models for infection of highly pathogenic viruses with outbreak potential. Zool Res 2018; 39:3–14 [View Article][PubMed]
     [Google Scholar]
  32. Bullard BL, Corder BN, Gorman MJ, Diamond MS, Weaver EA. Efficacy of a T Cell-Biased adenovirus vector as a Zika virus vaccine. Sci Rep 2018; 8:18017 [View Article][PubMed]
     [Google Scholar]
  33. López-Camacho C, Abbink P, Larocca RA, Dejnirattisai W, Boyd M et al. Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors. Nat Commun 2018; 9:2441 [View Article][PubMed]
     [Google Scholar]
  34. Yockey LJ, Jurado KA, Arora N, Millet A, Rakib T et al. Type I interferons instigate fetal demise after Zika virus infection. Sci Immunol 2018; 3:eaao1680 05 01 2018 [View Article][PubMed]
     [Google Scholar]
  35. Vaccines and vaccination against yellow fever, WHO Position paper-June 2013. Weekly Epidemiological Record (WER); 2013; 88269–284
  36. Japanese Encephalitis Vaccines WHO Position paper- February 2015. Weekly Epidemiological Record (WER); 2015; 9069–88
  37. Zhang N, Li C, Jiang S, Du L. Recent advances in the development of virus-like particle-based flavivirus vaccines. Vaccines 2020; 8:481–502 [View Article]
     [Google Scholar]
  38. Owens RJ, Rose JK. Cytoplasmic domain requirement for incorporation of a foreign envelope protein into vesicular stomatitis virus. J Virol 1993; 67:360–365 [View Article][PubMed]
     [Google Scholar]
  39. Robison CS, Whitt MA. The membrane-proximal stem region of vesicular stomatitis virus G protein confers efficient virus assembly. J Virol 2000; 74:2239–2246 [View Article][PubMed]
     [Google Scholar]
  40. Katzelnick LC, Narvaez C, Arguello S, Lopez Mercado B, Collado D et al. Zika virus infection enhances future risk of severe dengue disease. Science 2020; 369:1123–1128 [View Article][PubMed]
     [Google Scholar]
  41. Betancourt D, de Queiroz NMGP, Xia T, Ahn J, Barber GN. Cutting edge: innate immune augmenting vesicular stomatitis virus expressing Zika virus proteins confers protective immunity. J Immunol 2017; 198:3023–3028 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001588
Loading
Induction of protective immune responses against a lethal Zika virus challenge post-vaccination with a dual serotype of recombinant vesicular stomatitis virus carrying the genetically modified Zika virus E protein gene
J. Gen. Virol. 102, 001588 (2021); https://doi.org/10.1099/jgv.0.001588
/content/journal/jgv/10.1099/jgv.0.001588
/content/journal/jgv/10.1099/jgv.0.001588
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error